| 2025-01-30 14-08-07 | Sciatica is not significantly reduced at 3 months after after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-15-27 | Back Pain in the Lumbar Spine is reduced by an average of 71% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-13-47 | Back Pain in the Lumbar Spine is reduced by an average of 69% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-11-56 | Back Pain in the Lumbar Spine is reduced by an average of 62% at 3 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-29 10-39-27 | A reduction in posterior Intervertebral Disc (IVD) bulge size by >= 25% correlates with better NPS scores compared with <25% at 6 months post-injection of an average of 23 million Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Nucleus Pulposus and Annulus Fibrosus of L4-L5 or L5-S1 |
| 2025-01-29 10-27-22 | 85% of patients have a decrease in posterior Intervertebral Disc (IVD) bulge size 6 months on average post-injection of an average of 23 million Hypoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into the Nucleus Pulposus and Annulus Fibrosus of L4-L5 or L5-S1 |